Clinical trials: Metastatic Solid Malignancies
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Advanced Solid Tumors
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05774873
- Testing
- IBI334
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neoplasms
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of MOXR0916 administered intravenously in participants with locally advanced or…
- Trial name
- NCT02219724
- Testing
- MOXR0916
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Adult, Mesothelioma
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or…
- Conditions
- Solid Tumor, Adult, Mesothelioma, NSCLC
- Trial name
- NCT04665206
- Testing
- VT3989, Nivolumab & Ipilimumab, Osimertinib
- Where
- 12 sites in United States, Australia
- Volunteers
- 434 people
- Sponsor
- Vivace Therapeutics, Inc
Solid Tumor
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.
- Trial name
- NCT03733587
- Testing
- GX-I7, Cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Genexine, Inc.
Advanced Cancer, Metastatic Solid Tumors
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors
- Trial name
- NCT01976143
- Testing
- NKTR-102
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Nektar Therapeutics
Solid Tumors
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in…
- Trial name
- NCT04613492
- Testing
- MEDI9253, Durvalumab
- Where
- 8 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Solid Tumor, Advanced Solid Tumor
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-106 in adults with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07893535
- Testing
- BON-106
- Volunteers
- 96 people
- Sponsor
- BeOne Medicines
Solid Tumors
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360 when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid…
- Trial name
- NCT06536400
- Testing
- HSK42360
- Where
- 13 sites in China
- Volunteers
- 316 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Advanced/Metastatic Solid Tumors
Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.
- Trial name
- NCT01092052
- Testing
- NMS-1116354
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Nerviano Medical Sciences
Solid Tumors
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint…
- Trial name
- NCT04303858
- Testing
- Eciskafusp Alfa, Atezolizumab
- Where
- 12 sites in Belgium, Denmark and 3 more
- Volunteers
- 189 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). In preclinical studies, it demonstrated strong activity against PI3K p110α in vitro and in vivo, and inhibited tumor cell…
- Trial name
- NCT04631835
- Testing
- HS-10352
- Where
- 3 sites in China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Malignant Melanoma, Melanoma
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body.
- Conditions
- Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
- Trial name
- NCT06799533
- Testing
- PF-08046031
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Metastatic Solid Tumor
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05935098
- Testing
- BGB-A3055, Tislelizumab, Chemotherapy
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 99 people
- Sponsor
- BeiGene
Solid Tumor, Adult, Advanced Solid Tumor
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT04761198
- Testing
- Etigilimab, Nivolumab
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 76 people
- Sponsor
- Mereo BioPharma
Colorectal Cancer, Colorectal Cancer (CRC)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal…
- Conditions
- Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC
- Trial name
- NCT07321106
- Testing
- CBI-1214
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cartography Biosciences
Metastatic Solid Tumors
First in Human Study of M6223
The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks…
- Trial name
- NCT04457778
- Testing
- M6223, Bintrafusp alfa
- Where
- 4 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma
A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic…
- Conditions
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Trial name
- NCT06782555
- Testing
- Evofosfamide, Zalifrelimab, Balstilimab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- ImmunoGenesis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.